ImmuneWalk Therapeutics
Recent Finacing
Seed
Recent Raise
$7M
ImmuneWalk Therapeutics is a clinical-stage biotech developing IW-601, an engineered monoclonal antibody that inhibits monocyte migration via a novel adhesion checkpoint, currently in Phase 1 POINTGUARD trials.
Highlights
Focus Areas
Biotechnology
Financials
$7M
Total Raised
1
Funding round